Compare AbbVie Inc (ABBV) vs Icl Group Ltd (ICL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Icl Group Ltd — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Icl Group Ltd trades at $5.08 (market cap $6.49B). The key difference: AbbVie Inc is far larger — about 69.3× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.85%). Which is the better fit depends on your goals.
| ABBV | ICL | |
|---|---|---|
Market Cap | $449.91B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $261.07 | $7.23 |
52-Week Low | $184.85 | $4.80 |
Enterprise Value | $513.38B | $9.06B |
Dividend Yield | 2.72% | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
ICL trades at $4.95, down 1.59% on the day, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and announced a $0.05 dividend for H1 2026. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation metrics show a P/E of 24.05 and P/S of 0.88. Recent news highlights the completion of an $800 million senior notes offering to manage debt.
The outlook is mixed; strong cash flow and dividend payments provide stability, but declining profit margins and bearish analyst sentiment pose risks. Investment opportunity lies in operational improvements and potash market exposure, though investors face headwinds from raw material costs and foreign exchange volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
